首页> 美国卫生研究院文献>Springer Open Choice >Polygenic Risk Score Analysis of Alzheimer’s Disease inCases without APOE4 or APOE2 Alleles
【2h】

Polygenic Risk Score Analysis of Alzheimer’s Disease inCases without APOE4 or APOE2 Alleles

机译:阿尔茨海默氏病的多基因风险评分分析没有APOE4或APOE2等位基因的病例

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The We and others have previously shown that polygenic risk score analysis (PRS) has considerable predictive utility for identifying those at high risk of developing Alzheimer’s disease (AD) with an area under the curve (AUC) of >0.8. However, by far the greatest determinant of this risk is the apolipoprotein E locus with the E4 allele alone giving an AUC of ∼0.68 and the inclusion of the protective E2 allele increasing this to ∼0.69 in a clinical cohort. An important question is to determine how good PRS is at predicting risk in those who do not carry the E4 allele (E3 homozygotes, E3E2 and E2E2) and in those who carry neither the E4 or E2 allele (i.e. E3 homozygotes). Previous studies have shown that PRS remains a significant predictor of AD risk in clinical cohorts after controlling for APOE ε4 carrier status. In this study we assess the accuracy of PRS prediction in a cohort of pathologically confirmed AD cases and controls. The exclusion of APOE4 carriers has surprisingly little effect on the PRS prediction accuracy (AUC ∼0.83 [95% CI: 0.80-0.86]), and the accuracy remained higher than that in clinical cohorts with APOE included as a predictor. From a practical perspective this suggests that PRS analysis will have predictive utility even in E4 negative individuals and may be useful in clinical trial design.
机译:We和其他人先前已经表明,多基因风险评分分析(PRS)具有相当大的预测实用性,可用于识别曲线下面积(AUC)大于0.8的那些罹患阿尔茨海默氏病(AD)的高风险人群。然而,到目前为止,这种风险的最大决定因素是载脂蛋白E基因座,仅E4等位基因在AUC中的AUC约为0.68,而保护性E2等位基因的纳入在临床队列中将其AUC升至约0.69。一个重要的问题是确定在不携带E4等位基因(E3纯合子,E3E2和E2E2)的人和既不携带E4或E2等位基因(即E3纯合子)的人中PRS预测风险的能力如何。先前的研究表明,在控制APOEε4携带者状态后,PRS仍是临床队列中AD风险的重要预测指标。在这项研究中,我们评估了一组经病理证实的AD病例和对照的PRS预测的准确性。排除APOE4携带者对PRS的预测准确性几乎没有影响(AUC约为0.83 [95%CI:0.80-0.86]),并且其准确性仍高于以APOE作为预测指标的临床人群。从实践的角度来看,这表明PRS分析即使在E4阴性个体中也具有预测效用,可能在临床试验设计中有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号